Sugi Predict

Sugi Predict / Compounds / SCHEMBL2726581

SCHEMBL2726581

SCHEMBL2726581

COC1(OC)CCN(C(=O)OC(C)(C)C)CC1O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ NR1H2 P55055 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ EPHX2 P34913 1/20 0.39
▸ RECQL P46063 1/20 0.38
▸ EPHX1 P07099 1/20 0.38
▸ DDB1 Q16531 1/20 0.37
▸ CRBN Q96SW2 1/20 0.37
▸ CHRM2 P08172 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ ALK Q9UM73 1/20 0.36
▸ PDE4B Q07343 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3026628 0.84 USP2 (0.41) USP2SMN1; SMN2NR1H2ALDH1A1MEN1
SCHEMBL15459810 0.84 USP2 (0.41) USP2SMN1; SMN2NR1H2ALDH1A1MEN1
SCHEMBL30186133 0.83 USP2 (0.45) USP2SMN1; SMN2NR1H2ALDH1A1MEN1
SCHEMBL2904469 0.83 USP2 (0.45) USP2SMN1; SMN2NR1H2ALDH1A1MEN1
SCHEMBL23578678 0.81 USP2 (0.44) USP2SMN1; SMN2NR1H2ALDH1A1MEN1
SCHEMBL29959428 0.81 USP2 (0.44) USP2SMN1; SMN2NR1H2ALDH1A1MEN1
SCHEMBL734925 0.81 USP2 (0.44) USP2SMN1; SMN2NR1H2ALDH1A1MEN1
SCHEMBL29959344 0.81 USP2 (0.44) USP2SMN1; SMN2NR1H2ALDH1A1MEN1
SCHEMBL9942499 0.81 USP2 (0.44) USP2SMN1; SMN2NR1H2ALDH1A1MEN1
SCHEMBL733741 0.81 USP2 (0.44) USP2SMN1; SMN2NR1H2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304574-A1 3,4,6,7-TETRAHYDRO-2,7-NAPHTHYRIDINE-2(1H)-CARBOXAMIDE DERIVATIVES AS GPR65 INHIBITORS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES Pathios Therapeutics Limited (GB) 2025-10-02 — — US disclosed
US-20250074890-A1 CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-03-06 — — US disclosed
EP-4472963-A1 DGK TARGETING COMPOUNDS AND USES THEREOF Arvinas Operations, Inc. (US) 2024-12-11 — — EP disclosed
CN-118946556-A DGK targeting compounds and uses thereof 阿维纳斯运营公司 2024-11-12 — — CN disclosed
CN-114901660-B Substituted bicyclic compounds useful as T cell activators 百时美施贵宝公司 2024-10-15 — — CN disclosed
EP-4380919-A1 CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS Dana-Farber Cancer Institute, Inc. (US) 2024-06-12 — — EP disclosed
CN-117980290-A Cyanopyridine and cyanopyrimidine BCL6 degrading agents 达纳－法伯癌症研究所公司 2024-05-03 — — CN disclosed
US-11964973-B2 Substituted bicyclic compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2024-04-23 — — US disclosed
WO-2023187391-A1 3,4,6,7-TETRAHYDRO-2,7-NAPHTHYRIDINE-2(1H)-CARBOXAMIDE DERIVATIVES AS GPR65 INHIBITORS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES Pathios Therapeutics Limited (GB) 2023-10-05 — — WO disclosed
WO-2023150186-A1 DGK TARGETING COMPOUNDS AND USES THEREOF ARVINAS OPERATIONS, INC. (US) 2023-08-10 — — WO disclosed
US-7700624-B2 3-aminocyclopentanecrboxamides as modulators of chemokine receptors INCYTE CORPORATION (US) 2010-04-20 — — US disclosed
US-7700624-B2 3-aminocyclopentanecrboxamides as modulators of chemokine receptors INCYTE CORPORATION (US) 2010-04-20 — — US disclosed
EP-2064209-A1 PYRROLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY AstraZeneca AB (SE) 2009-06-03 — — EP disclosed
WO-2009033581-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-03-19 — — WO disclosed
EP-1971576-A2 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS Incyte Corporation (US) 2008-09-24 — — EP disclosed
WO-2008020222-A1 PYRROLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY ASTRAZENECA AB (SE) 2008-02-21 — — WO disclosed
US-20070149532-A1 3-Aminocyclopentanecarboxamides as Modulators of Chemokine Receptors INCYTE CORPORATION 2007-06-28 — — US disclosed
US-20070149532-A1 3-Aminocyclopentanecarboxamides as Modulators of Chemokine Receptors INCYTE CORPORATION 2007-06-28 — — US disclosed
US-20070149532-A1 3-Aminocyclopentanecarboxamides as Modulators of Chemokine Receptors INCYTE CORPORATION 2007-06-28 — — US disclosed
WO-2007072201-A2 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS INCYTE CORPORATION (US) 2007-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074890-A1 CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS BCL6, BCL6B, BCOR USP2 908/4885SMN1; SMN2 2805/4885NR1H2 3442/4885
US-20070149532-A1 3-Aminocyclopentanecarboxamides as Modulators of Chemokine Receptors CCR5, CCR2, ACKR3 USP2 4055/4885SMN1; SMN2 4747/4885NR1H2 168/4885
US-11964973-B2 Substituted bicyclic compounds useful as T cell activators DGKA, DGKZ, DGKK USP2 4584/4885SMN1; SMN2 4545/4885NR1H2 1119/4885
US-20250304574-A1 3,4,6,7-TETRAHYDRO-2,7-NAPHTHYRIDINE-2(1H)-CARBOXAMIDE DERIVATIVES AS GPR65 INHIBITORS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES GPR65, GPR52, GPR68 USP2 4107/4885SMN1; SMN2 4666/4885NR1H2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.